Cargando…

Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer

BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Lahmadi, Mohamed, Beddar, Leila, Rouibah, Amira Lyna, Boumegoura, Ali, Boufendi, Houda, Temim, Asma, Nini, Anissa, Sellam, Feriel, Satta, Dalila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325123/
https://www.ncbi.nlm.nih.gov/pubmed/33906297
http://dx.doi.org/10.31557/APJCP.2021.22.4.1063
_version_ 1783731504824713216
author Lahmadi, Mohamed
Beddar, Leila
Rouibah, Amira Lyna
Boumegoura, Ali
Boufendi, Houda
Temim, Asma
Nini, Anissa
Sellam, Feriel
Satta, Dalila
author_facet Lahmadi, Mohamed
Beddar, Leila
Rouibah, Amira Lyna
Boumegoura, Ali
Boufendi, Houda
Temim, Asma
Nini, Anissa
Sellam, Feriel
Satta, Dalila
author_sort Lahmadi, Mohamed
collection PubMed
description BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This retrospective study aimed to investigate the EGFR mutation status in Algerian NSCLC patients and its association with clinicopathological features. METHODS: We examined the presence of EGFR mutations (Exons 19-21) in 58 unselected NSCLC samples using PCR followed by direct sequencing. RESULTS: The present study included 53 (91.4%) men and 5 (8.6%) women, with a median age of 59 (ranging from 44 to 94 years old). EGFR mutations were detected in 23 patients, with an overall rate of 39.6%. There were 21 (91.3%) cases with the exon-21 L585R single mutation and two (8.7%) with dual mutations of exon-19 deletions and L585R. EGFR mutations were more frequently found in patients with confirmed adenocarcinoma (14/27, 51.8%) than in non-adenomatous NCSCL subtypes (3/14, 21.4%; p=0.03). Furthermore, early stages of the disease were significantly associated with a higher rate of EGFR mutations (14/27, 51.8%) compared with those at advanced stage (5/21, 23.8%; p=0.02). There were no significant differences in EGFR mutation frequency by age, gender, or smoking status. CONCLUSION: We found that Algerian NSCLC patients exhibited a high rate of EGFR mutations, which was quite similar to that in Asians population rather than Caucasian patients. Thus, TKI-based treatments may be more beneficial for Algerian patients with NSCLC. Further studies using a large number of patients are required to confirm our preliminary findings.
format Online
Article
Text
id pubmed-8325123
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-83251232021-08-06 Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer Lahmadi, Mohamed Beddar, Leila Rouibah, Amira Lyna Boumegoura, Ali Boufendi, Houda Temim, Asma Nini, Anissa Sellam, Feriel Satta, Dalila Asian Pac J Cancer Prev Research Article BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This retrospective study aimed to investigate the EGFR mutation status in Algerian NSCLC patients and its association with clinicopathological features. METHODS: We examined the presence of EGFR mutations (Exons 19-21) in 58 unselected NSCLC samples using PCR followed by direct sequencing. RESULTS: The present study included 53 (91.4%) men and 5 (8.6%) women, with a median age of 59 (ranging from 44 to 94 years old). EGFR mutations were detected in 23 patients, with an overall rate of 39.6%. There were 21 (91.3%) cases with the exon-21 L585R single mutation and two (8.7%) with dual mutations of exon-19 deletions and L585R. EGFR mutations were more frequently found in patients with confirmed adenocarcinoma (14/27, 51.8%) than in non-adenomatous NCSCL subtypes (3/14, 21.4%; p=0.03). Furthermore, early stages of the disease were significantly associated with a higher rate of EGFR mutations (14/27, 51.8%) compared with those at advanced stage (5/21, 23.8%; p=0.02). There were no significant differences in EGFR mutation frequency by age, gender, or smoking status. CONCLUSION: We found that Algerian NSCLC patients exhibited a high rate of EGFR mutations, which was quite similar to that in Asians population rather than Caucasian patients. Thus, TKI-based treatments may be more beneficial for Algerian patients with NSCLC. Further studies using a large number of patients are required to confirm our preliminary findings. West Asia Organization for Cancer Prevention 2021-04 /pmc/articles/PMC8325123/ /pubmed/33906297 http://dx.doi.org/10.31557/APJCP.2021.22.4.1063 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lahmadi, Mohamed
Beddar, Leila
Rouibah, Amira Lyna
Boumegoura, Ali
Boufendi, Houda
Temim, Asma
Nini, Anissa
Sellam, Feriel
Satta, Dalila
Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer
title Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer
title_full Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer
title_fullStr Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer
title_full_unstemmed Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer
title_short Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer
title_sort analysis of egfr mutation status in algerian patients with non-small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325123/
https://www.ncbi.nlm.nih.gov/pubmed/33906297
http://dx.doi.org/10.31557/APJCP.2021.22.4.1063
work_keys_str_mv AT lahmadimohamed analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer
AT beddarleila analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer
AT rouibahamiralyna analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer
AT boumegouraali analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer
AT boufendihouda analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer
AT temimasma analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer
AT ninianissa analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer
AT sellamferiel analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer
AT sattadalila analysisofegfrmutationstatusinalgerianpatientswithnonsmallcelllungcancer